Sanofi (NASDAQ:SNY) Given Consensus Rating of “Hold” by Brokerages

Shares of Sanofi (NASDAQ:SNY) have earned an average recommendation of “Hold” from the fifteen research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation, three have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $49.50.

SNY has been the topic of several recent research reports. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Argus upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a report on Monday, April 20th. Wall Street Zen cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Morgan Stanley set a $49.00 price target on Sanofi in a research note on Wednesday, July 8th.

Sanofi Price Performance

Shares of SNY stock opened at $43.46 on Monday. The stock has a 50-day moving average price of $43.31 and a 200 day moving average price of $45.04. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. The firm has a market cap of $105.37 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 1.08 and a beta of 0.35. Sanofi has a 12 month low of $40.89 and a 12 month high of $52.68.

Institutional Investors Weigh In On Sanofi

Several large investors have recently bought and sold shares of SNY. Trust Co. of Vermont bought a new stake in shares of Sanofi in the 2nd quarter valued at $212,000. Fiduciary Financial Group LLC grew its holdings in shares of Sanofi by 33.8% during the second quarter. Fiduciary Financial Group LLC now owns 8,403 shares of the company’s stock worth $358,000 after buying an additional 2,124 shares in the last quarter. Fulton Bank N.A. raised its position in Sanofi by 5.6% in the 2nd quarter. Fulton Bank N.A. now owns 68,196 shares of the company’s stock valued at $2,909,000 after buying an additional 3,623 shares during the last quarter. First Bank & Trust lifted its stake in Sanofi by 23.4% in the 2nd quarter. First Bank & Trust now owns 83,933 shares of the company’s stock valued at $3,581,000 after acquiring an additional 15,937 shares in the last quarter. Finally, Focus Financial Network Inc. lifted its stake in Sanofi by 9.2% in the 2nd quarter. Focus Financial Network Inc. now owns 5,302 shares of the company’s stock valued at $226,000 after acquiring an additional 446 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.